Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

"Conflict of Interest Disclosures Alberto Alvarez‐Larrán participated on advisory boards and received speaker and consulting fees from Novartis, AOP, and Celgene. Francisca Ferrer‐Marín received research support from Incyte and CTI, speaker and consulting fees from Novartis and Incyte, and meeting support from Novartis. Manuel Pérez‐Encinas participated on an advisory board and received speaker fees from Novartis. Regina García participated on advisory boards for and received payments for lectures and expert testimony and support for attending meetings from Novartis, Jansen, and AbbVie.Valentín García‐Gutiérrez received speaker honorarium and support for attending meetings from Novartis and Incyte, and participated on advisory boards for Novartis and Incyte. Clara M. Martínez received payments or honoraria from Novartis. Maria Laura Fox received consulting fees from Sierra Oncology and Novartis, payment for lectures from Novartis, and support for attending meetings from Novartis and Sanofi. Rosa Ayala received speaker honoraria from Astellas, Celgene, and Novartis and participated on advisory boards for Novartis and Incyte. Ilda Murillo received support for attending meetings and/or travel from Novartis and Janssen. Rafael del Orbe‐Barreto received support for attending meetings and/or travel from Novartis. Gonzalo Caballero received support for attending meetings and/or travel from Novartis and Janssen and participated on a board for AstraZeneca. Marta Garrote received support for attending meetings from Roche and Transglobal. M. Isabel Mata‐Vazquez participated on advisory boards and received speaker and consulting fees and support for attending meetings from Incyte and Novartis. Gonzalo Carreño‐Tarragona received payments or honoraria from Novartis, Incyte, Astellas, SEHH (Sociedad Española de Hematología y Hemoterapia), and AMHH (Asociación Madrileña de Hematología y Hemoterapia). Juan Carlos Hernández‐Boluda reported consulting fees from AOP Pharma, Celgene, and BMS; payments or honoraria from Novartis; support for attending meetings and/or travel from Incyte; and participation on boards for Celgene and BMS. The other authors made no disclosures."

"Instituto de Salud Carlos III 10.13039/501100004587; Novartis for developing the Spanish Registry of Polycythemia Vera"